MBX BIOSCIENCES INC. - COMMON STOCK

MBX Biosciences to Participate in Citizens and RBC May Investor Conferences

22 أبريل 2025 08:00:00 بحسب Nasdaq GlobeNewswire

MBX Biosciences Appoints Veteran Pharmaceutical Executive Steve Hoerter to Board of Directors

07 أبريل 2025 08:00:01 بحسب Nasdaq GlobeNewswire

MBX Biosciences to Participate in the 24th Annual Needham Virtual Healthcare Conference

26 مارس 2025 08:00:01 بحسب Nasdaq GlobeNewswire

MBX Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights

17 مارس 2025 08:00:00 بحسب Nasdaq GlobeNewswire

MBX Biosciences Announces Additions to Leadership Team

05 مارس 2025 08:00:00 بحسب Nasdaq GlobeNewswire

MBX Biosciences Completes Enrollment in Phase 2 Avail™ Trial of MBX 2109 (Canvuparatide) for Hypoparathyroidism

03 مارس 2025 08:00:00 بحسب Nasdaq GlobeNewswire

MBX Biosciences to Participate in March Investor Conferences

18 فبراير 2025 08:00:00 بحسب Nasdaq GlobeNewswire

MBX Biosciences to Participate in Upcoming February Investor Conferences

23 يناير 2025 08:00:00 بحسب Nasdaq GlobeNewswire

MBX Biosciences Announces Positive Phase 1 Topline Results for MBX 1416 for the Treatment of Post-bariatric Hypoglycemia

07 يناير 2025 07:00:00 بحسب Nasdaq GlobeNewswire

MBX Biosciences to Participate in 43rd Annual J.P. Morgan Healthcare Conference

18 ديسمبر 2024 08:00:00 بحسب Nasdaq GlobeNewswire

MBX Biosciences Announces MBX 2109 Phase 1 Study Results Published in The Journal of Clinical Endocrinology and Metabolism

02 ديسمبر 2024 08:00:00 بحسب Nasdaq GlobeNewswire

MBX Biosciences Announces Last Subject Last Visit in Phase 1 Trial of MBX 1416 for the Treatment of Post-Bariatric Hypoglycemia

18 نوفمبر 2024 08:00:00 بحسب Nasdaq GlobeNewswire

MBX Biosciences Reports Third Quarter 2024 Financial Results and Provides Business Update

07 نوفمبر 2024 08:00:01 بحسب Nasdaq GlobeNewswire

MBX Biosciences to Participate in Upcoming November Investor Conferences

28 أكتوبر 2024 08:00:00 بحسب Nasdaq GlobeNewswire

MBX Biosciences Presents MBX 2109 Phase 2 Avail™ Hypoparathyroidism Trial Rationale and Design at the ASBMR 2024 Annual Meeting

30 سبتمبر 2024 08:00:00 بحسب Nasdaq GlobeNewswire

MBX Biosciences Announces Closing of Upsized Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

16 سبتمبر 2024 16:05:00 بحسب Nasdaq GlobeNewswire